ReportsnReports.com: Lung Cancer Vaccines: Pipeline, Strategies and Clinical
Biopharma Report's "Lung Cancer Vaccines: Pipeline, Strategies and Clinical" is now available at ReportsnReports.com.
- Dallas, TX (1888PressRelease) October 13, 2011 - Report Summary
This report provides a comprehensive review of 42 candidate vaccines that are being evaluated for the treatment of lung cancer, covering pipeline, disease-targeting strategies and clinical findings. These vaccines are directed at 24 antigens or antigen combinations.
Globally, lung cancer is the most common cancer and in 2008 there were an estimated 1.6 million new cases and 1.4 million deaths (almost 20% of all cancer deaths) caused by this disease. Five-year survival rates are also low (15-20%) compared to other common cancers. In the US, studies have shown that lung cancer-care costs (in 2006) were the third highest of all cancers, while indirect costs (2005) were higher than for any other cancer.
Browse All: http://www.reportsnreports.com/market-research/pharmaceuticals/
Patient needs and the high burden of lung cancer drive the development of new therapies. While improvements have been seen in diagnosis and treatments (surgery, radiotherapy, chemotherapy and targeted medicine), new therapies that build on the capabilities of existing approaches, are urgently required. Today, developments continue to be made in treatments for lung cancer; in chemotherapy, new medical combinations and targeted molecules. In particular, advances are being seen in the field of immunotherapy; in the development of new therapeutic antibodies and therapeutic vaccines.
Buy Now: http://www.reportsnreports.com/reports/131822-lung-cancer-vaccines-pipeline-strategies-and-clinical.html
This Report
This report (see brochure) provides a comprehensive review of lung cancer market for vaccines and reviews R&D and clinical developments in the treatment of lung cancer as the primary indication, as well as studies that are evaluating lung cancer alongside other cancers.
Today, more than 40 candidate lung cancer vaccines are in development or being evaluated for the treatment of lung cancer, most of which are already in clinical trials. This field is also showing substantial innovation and 24 different antigen/multiple antigen targeting strategies are being investigated. For the purpose of this report, multiple antigen targeting approaches have been treated as single strategies. This report gives an overview of the status and clinical findings of these candidate vaccines, and gives developmental and market-related perspectives in this rapidly developing field.
About Us:
ReportsnReports is an online library of over 100,000+ market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.
Follow us on Twitter: http://twitter.com/marketsreports
Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: + 1 888 391 5441
E-mail: sales ( @ ) reportsandreports dot com
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam